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sion medicine are interchangeable terms that describe an
approach to the treatment of disease that harnesses our
understanding of the molecular basis and mechanisms of
a given disease and matches appropriate therapeutic inter-
ventions.1 Breast cancer represents a diverse collection of
malignant diseases of the breast with highly variable clinical
behaviors and disparate responses to therapy.2 The perplex-
ing challenge of patient management for the clinician is re-
ﬂected in the observation that among breast cancer patients
with similar disease (based on traditional histopathological
measures) and similar therapeutic strategy, some patients
will be cured (and thereafter live a normal lifespan) whereas
others will progress to premature death. In fact, we now
recognize that breast cancer is tremendously complex in its
molecular pathogenesis, natural history, and biology.2
Breast cancer affects not only women but also men (1% of
cases). It occurs both as sporadic malignant disease and as
hereditary disease. Hereditary breast cancers manifest in
patients with strong genetic predisposition involving BRCA1
and BRCA2 genes, as well as in patients with familial cancer
syndromes involving other genes, such as TP53.3 Most breast
cancers occur in women without identiﬁable risk factors, and
strong hereditary predisposition accounts for only 5% to 10%
of cases.4 Often, the genetic component of disease predis-
position may reﬂect small but measurable risks associated
with polymorphic sequence variations at multiple loci.5
Breast cancer occurs in both young and old patients, and
affects people of all races and ethnicities. Numerous other
risk factors are associated with breast cancer development,
including reproductive factors, dietary factors, obesity, and
environmental exposure.6 Beyond the highly variable nature
of breast cancer etiology, the malignant disease is also
highly complex. Recent studies have dissected the molecularCopyright ª 2013 American Society for Investigative Pathology.
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http://dx.doi.org/10.1016/j.ajpath.2013.08.001biology of clinical breast cancers through detailed analysis of
genomics (gene mutations and copy number variations),
transcriptomics (expression of structural genes and non-
coding RNAs), epigenomics (DNA methylation and histone
modiﬁcations), and proteomics (changes in protein expres-
sion and functionality). These studies have revealed immense
diversity in individual breast cancers and across cohorts of
breast cancer patients. The emerging picture of the molecular
biology of breast cancer suggests that there are few dominant
driver mutations reﬂecting speciﬁc genes or pathways as
a required event leading to tumorigenesis. Rather, there are
numerous driver or passenger mutations in a given breast
cancer, as well as epigenetic alterations that signiﬁcantly
impact the expression of individual genes and the overall
gene expression signature. Ultimately, the clinical behavior
of a given breast cancer reﬂects its unique combination of
activating and inactivating genetic mutations and epigenetic
alterations that give rise to cancer-associated phenotypes (eg,
uncontrolled cell proliferation, loss of cellular differentiation,
local invasiveness, and ability to spread to distant tissue
sites).
Personalized medicine for the routine clinical management
of breast cancer patients is a lofty goal that will require
expansion of our knowledge of the molecular underpinnings
of this disease and its various subtypes.7 With increased
investigation of the genomics, transcriptomics, epigenomics,
and proteomics of breast cancer, our understanding of the
mechanisms that drive the development and progression of
this group of diseases will expand. In addition, new molec-
ular targets for drug therapy may be identiﬁed, and new
biomarkers may emerge that are useful in breast cancer
detection, prognostication, and therapy guidance. Basic
Guest Editorialscience research represents the foundation for breast cancer
personalized medicine, cataloging the molecular alterations
and characterizing their effects on breast tumorigenesis and
progression. Applied science will harness the information
generated related to the biology of breast cancer to select
genes and pathways for development of targeted therapies
and innovative drug designs and to investigate practical
biomarkers for clinical management. Equally important are
clinical studies that provide insight into patient outcomes
(both disease-free and long-term survival) in response to
speciﬁc therapeutic strategies with consideration of the
molecular characteristics of the breast cancer and of the
patient. Utilization of currently available technologies in
investigational studies that span basic, applied, and clinical
sciences will elucidate the molecular underpinnings of breast
cancer biology and how the character of individual breast
cancers inﬂuence outcomes. Even if the critical molecular
events are linked with patient responses to therapy in breast
cancer, challenges will remain with respect to the imple-
mentation of personalized medicine in the clinical setting.8
This special Breast Cancer Theme Issue of The American
Journal of Pathology includes seven reviews covering
major topics related to the molecular pathogenesis of breast
cancer and implications for personalized breast cancer
therapy. Ghousaini et al9 provide an overview of the
genetics of breast cancer susceptibility, including discussion
of both rare high-penetrance alleles (ie, BRCA1 and BRCA2)
and common low-penetrance alleles, many of which are
newly identiﬁed. The involvement of these common low-
penetrance alleles and combinations thereof is extremely
important as these alleles may be involved in many sporadic
breast cancers. Stefansson and Esteller10 present a compre-
hensive review of breast cancer epigenetics. Epigenetics
holds signiﬁcant implications for breast cancer treatment
reﬂecting the importance of gene expression signatures to
breast cancer biology as well as recognizing that epigenetic
alterations are reversible and may provide the basis for new
therapeutic approaches. Engebraaten et al11 review our
current understanding of triple-negative breast cancers and
potential new targets for therapy that might improve
disease-free and long-term outcomes of patients afﬂicted by
these difﬁcult-to-treat breast cancers. De Abreu et al12
describe the state of the art in breast cancer molecular
diagnostics and the importance of the clinical diagnostics
laboratory in realizing personalized breast cancer medicine.
Marino et al13 discuss progression of breast cancer to
metastatic disease, the molecular evolution occurring during
this process, and implications for prevention of metastasis or
treatment in the individual patient. Mohamed et al14 provide
a comprehensive examination of targeted therapies that areThe American Journal of Pathology - ajp.amjpathol.orgcurrently used in the treatment of breast cancer and studies
on the identiﬁcation of novel molecular targets for breast
cancer drug development. Rivenbark et al15 discuss methods
for classiﬁcation of breast cancer, correspondence among
methods, and the extensive diversity that exist among breast
cancers based on molecular data. This review goes on to
discuss how breast cancer heterogeneity impinges on
accurate classiﬁcation of disease and implications for real-
ization of true personalized breast cancer therapy. This
collection of reviews provides the reader with information
from basic research, observations from clinical research, and
developments from applied research related to the past,
present, and future of breast cancer personalized medicine.References
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